The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers. Strikingly, 38% of participants did not fit clearly into any one of these groups and were considered indeterminant. The largest subset of indeterminants had elevated serum aminotransferases with low levels of HBV DNA (less than 10,000 iu/ mL). Subsequent determination of hepatitis B phenotype on the next available laboratory tests showed that 64% remained indeterminant. These findings call into question the validity of conventional staging of hepatitis B, in large part because of the substantial proportion of patients who do not fit readily into one of the usual stages or phases. Further studies are needed of the indeterminant category of chronic hepatitis B viral infection, including assessments of whether patients in this group are perhaps in transition to another phase or if they are a distinct phenotype with a need to assess liver disease severity and need for antiviral therapy. (ClinicalTrials.gov identifier NCT01263587).
| INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a frequent, serious human viral infection, affecting nearly 350 million persons worldwide and representing a major cause of morbidity and mortality from end-stage liver disease and hepatocellular carcinoma. 1 The natural history of this infection is complex, involving several phases or stages. Patients with higher levels of HBV DNA in serum and more active liver disease (as shown by elevated serum aminotransferase levels) are at higher risk of developing cirrhosis and hepatocellular carcinoma. an NIH-funded clinical network that has enrolled more than 2,000 participants with chronic HBV infection to provide a "pool" of potential participants for other studies, including treatment. 6 This manuscript describes the process of developing a computer algorithm for assigning participants into various phenotypes at baseline, to examine relationships with demographic, biochemical, immunological and epidemiological features and will be used ultimately to identify changes over time and the long-term clinical implications of different HBV phenotypes.
| METHODS
Participants were enrolled into one of the HBRN Cohort or Treatment studies, as previously described. 6 All participants were seropositive and prior serum alanine aminotransferase (ALT) levels were captured from participants' medical records and also entered into the database.
Liver biopsies were not routinely done in participants, so estimates of liver disease severity were made using FIB-4 (a parameter calculated using ALT and AST values, platelet count and age) and AST to platelet ratio (APRI), well-validated methods for estimating liver disease severity with a relatively high predictive value for detecting the presence of cirrhosis. 
| RESULTS
As of 26 January 2015, 2290 participants had been enrolled into one of the HBRN studies. The current analysis was limited to adults with chronic HBV infection, who were not on antiviral therapy and had undergone a treatment washout period of at least 6 months. The specific reasons for exclusion and numbers in each group are shown in the CONSORT diagram as Figure S1A . Among 1571 adult participants who met all inclusion criteria, 1390 had sufficient data available to allow a baseline phenotype to be determined ( Table S1 ) plus a single Canadian site, the University of Toronto, which contributed the highest number of participants (18% of the total). The demographic and clinical features of the three indeterminant groups are compared in Table 3 . Participants in the indeterminant To assess the impact of the low cut-off used to define normal ALT values (<30 U/L for men and <20 U/L for women), the computer algorithm was rerun using reported ULN for local laboratories, which in this study ranged from 24 to 78 U/L for men and women (median 48 U/L).
As might be expected, the indeterminant phenotype was less common (see Table 4 ; 22% vs. 38%) and the inactive carrier state more frequent (30% vs. 17%) using the local ULN definition. Objective determinations of phenotype based upon specific laboratory values were compared to the semi-subjective determination made by the enrolling principal investigator ( Table 5 ). The subjective assessments were more likely to place participants into a conventional phenotype, the proportion of cases designated as indeterminant being 13% by the physician investigator compared to 38% by computer using fixed ALT ULN values and 22% by computer using locally defined ALT ULN values.
| DISCUSSION
The relative risk for individuals with chronic HBV infection of developing progressive liver disease and HCC varies greatly, based largely on disease activity and level of viral replication and may be predicted by their phenotype. [17] [18] [19] [20] [21] [22] [23] Although these broad categories have been characterized as "phases" or "stages," there is little evidence that individual patients pass through each of these sequentially. However, transitions from one phase to another, and back, are well described, such as "seroconversion" in which HBeAg is lost, often associated with a decrease in serum HBV DNA levels and reduction in aminotransferase activity. 24, 25 Reactivation may also occur, typically in association with immune suppression for various reasons or sometimes simply spontaneously. 26 Variability in phenotype definitions has been exaggerated by technical advances over time in the assays used to measure HBV DNA with improvements in sensitivity and dynamic range, as well as variability in what is considered to be normal for serum ALT activity. 27, 28 Furthermore, much of the data upon which the description of these phases is based has been derived from studies done in Asia. 
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Among the three indeterminant groups, genotype B was most common in the group with HBeAg negative but high HBV DNA levels (indeterminant C, 58%), while genotype C was the most frequent among participants with HBeAg and low HBV DNA levels (indeterminant A, 37).
One of the key findings from our data and perhaps the most sur- them to be the most frequent phenotype (38% overall when using fixed ALT values). This is similar to the proportion of patients found to be "undetermined" in a study of a smaller cohort of Asian Americans.
31
It appears that current thinking about HBV infection is an oversimplification and does not match with the diversity of disease expression.
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Three distinct patterns of indeterminant hepatitis B could be determined and the significance of each of these patterns will need to be clarified, particularly with regard to their natural history and whether these patients should be offered antiviral therapy.
It is possible too that the use of a fixed low value to define normal ALT value may have artificially inflated the size of the indeterminant group, but this issue still persists even when using laboratory-specific definition of normal ALT. There has been some controversy about what is thought to represent the normal range for ALT levels. 33 Typically, these are determined by each local laboratory and might vary based on the equipment used to measure ALT and on the prevalent ALT levels among the normal control subjects used to calibrate the assay at that site. The fixed values of 30 U/L and 20 U/L, respectively, for men and T A B L E 3 Subset of participants in There were no obvious differences in alcohol consumption among participants in the various phenotypes. There were a few indeterminant B participants who were pregnant at baseline and the pregnant state is well known to cause disruptions to otherwise stable HBV infection. 34 Another interesting finding that emerged from this study is the fairly substantial discrepancy between the formal calculated phe- Finally, we tried to determine the stability or reproducibility of the computer-generated HBV phenotype and found that it was quite reproducible in all groups on the next available set of laboratory data, except for those with indeterminant C phenotype (HBeAg negative, high viral load), with only 32% remaining in the same category upon repeat testing. A long-term goal of the network will be to study changes in HBV phenotype over time and this exercise was an important one to define phenotype and determine it at baseline.
| SUMMARY AND CONCLUSIONS
In summary, we coin the term HBV phenotype to characterize the bio- 
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